A monoclonal antibody directed against lymphotoxin-α (LT-α) expressed by pathogenic T cells can prompt the clearance of these cells from the body (pages 766–773). The findings bring us one step closer to targeting only the cell populations that cause harm in autoimmune diseases while leaving beneficial arms of the immune system largely intact.
References
Caspi, R.R. Nat. Rev. Immunol. 8, 970–976 (2008).
Chiang, E. et al. Nat. Med. 15, 766–773 (2009).
O'Garra, A. & Arai, N. Trends Cell Biol. 10, 542–550 (2000).
Korn, T., Bettelli, E., Oukka, M. & Kuchroo, V.K. Annu. Rev. Immunol. 27, 485–517 (2009).
Abbas, A.R. Genes Immun. 6, 319–331 (2005).
Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Cell 133, 775–787 (2008).
Shevach, E.M. Immunity 30, 636–645 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hansen, A., Caspi, R. Targeting lymphotoxin depletes pathogenic T cells. Nat Med 15, 732–733 (2009). https://doi.org/10.1038/nm0709-732
Issue Date:
DOI: https://doi.org/10.1038/nm0709-732
- Springer Nature America, Inc.
This article is cited by
-
The silent progression of metastatic malignancy during the treatment with soluble tumor necrosis factor receptor
Clinical Rheumatology (2010)